Informe de inteligencia

Merck taps Isomorphic Labs' design engine to hunt small-molecule cancer drugs

The drugmaker will pair its own lab data with Isomorphic's drug design platform to pursue an undisclosed oncology target, keeping development rights.

INSIGHTEX Editorial Desk

2 min de lectura

Merck taps Isomorphic Labs' design engine to hunt small-molecule cancer drugsInforme de inteligencia

What happened

Merck has agreed to a research collaboration with Isomorphic Labs, an artificial intelligence drug design company, with the goal of finding small molecule candidates against a cancer target that neither company has named, STAT reported. The two companies announced the arrangement on Thursday and described the target as one of strategic importance to Merck.

Under the deal, Isomorphic will apply its proprietary drug design engine to wet lab data that Merck has already generated, according to officials from both companies. Merck will take on all work beyond discovery, handling clinical and preclinical work as well as manufacturing and commercialization of any products that emerge from the partnership.

George Addona, who leads discovery, preclinical development and translational medicine globally at Merck, said the company has a strong interest in the target and has already pursued it through internal research. He said combining those existing datasets with Isomorphic's discovery technology could make for a highly effective match.

Context

Isomorphic Labs builds its drug design work on Nobel-winning technology that can model how molecules bind to proteins, a capability central to designing small molecule drugs. The Merck collaboration is the latest in a series of agreements between Isomorphic and large pharmaceutical companies, reflecting growing pharma interest in applying artificial intelligence to early-stage drug discovery.

FuenteSTAT

El boletín

La semana tecnológica, en un solo correo.

Las crónicas que merecen su tiempo, cada semana. Cancele la suscripción cuando quiera.